The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut

• Published in: Canadian Respiratory Journal
• Main Authors: Anna Banerji, Vladimir Panzov, Michael Young, Bonita E Lee, Muhammad Mamdani, B Louise Giles, Marguerite Dennis, Johanne Morel, Danny Bisson, Bosco A Paes, Charles Hui, Jim Mahony
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2014
• Subjects: Diseases of the respiratory system; RC705-779; Nunavut
• Online Access: https://doi.org/10.1155/2014/941367; https://doaj.org/article/68c5697a65c54cfc9be367e8c5a1377c

BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant cardiac or chronic lung disease; however, the effectiveness of the program is unknown. The objective of the present multisite, hospital-based surveillance study was to estimate the effectiveness of palivizumab in infants <6 months of age in Nunavut for the 2009 and 2010 RSV seasons.